Marcadores
multiple sclerosis
disease modifying treatment
progressive multiple sclerosis
neurology
cladribine
equity
ms
natalizumab
primary progressive multiple sclerosis
multiple sclerosis therapy
neda
neuroscience
lower and middle income countries
nhs
neuroanatomy
#chariotms
#thinkhand
upper limb function
access to treatment
b cells
fingolimod
rebound disease
mri
neuronal loss
cerebral cortex
spinal cord
synapses
axonal loss
neuropathology
post mortem
immune therapy
side effects
adverse effects
health scam
social media
treatment
venoplasty
ccsvi
off-label
health economics
time matters
#ectrims2016
spms
disease progression
ppms
pml
tysabri
laquinimod
arpeggio
disease
trials
Ver mais
Apresentações
(10)Documentos
(9)Marcadores
multiple sclerosis
disease modifying treatment
progressive multiple sclerosis
neurology
cladribine
equity
ms
natalizumab
primary progressive multiple sclerosis
multiple sclerosis therapy
neda
neuroscience
lower and middle income countries
nhs
neuroanatomy
#chariotms
#thinkhand
upper limb function
access to treatment
b cells
fingolimod
rebound disease
mri
neuronal loss
cerebral cortex
spinal cord
synapses
axonal loss
neuropathology
post mortem
immune therapy
side effects
adverse effects
health scam
social media
treatment
venoplasty
ccsvi
off-label
health economics
time matters
#ectrims2016
spms
disease progression
ppms
pml
tysabri
laquinimod
arpeggio
disease
trials
Ver mais